Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer.
about
Outcomes and quality of life following breast cancer treatment in older women: when, why, how much, and what do women want?Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies.Anatomical variations of the axilla.A pilot, prospective evaluation of a novel alternative for maintenance therapy of breast cancer-associated lymphedema [ISRCTN76522412].Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review.Obesity increases inflammation and impairs lymphatic function in a mouse model of lymphedema.Upper-body morbidity following breast cancer treatment is common, may persist longer-term and adversely influences quality of lifeRadiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF-beta1-mediated tissue fibrosis.Breast Cancer EDGE Task Force Outcomes: Clinical Measures of Pain.Breast cancer-related lymphedema: women's experiences with an underestimated condition.Risk of decline in upper-body function and symptoms among older breast cancer patientsOptimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma: a decision analysis.Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery.A safety and efficacy pilot study of acupuncture for the treatment of chronic lymphoedema.Predictors of Health Care Use of Women with Breast Cancer: A Systematic Review.Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients.Sequelae following axillary lymph node dissection for breast cancer.Quality indicators for sentinel lymph node biopsy: is there room for improvement?Risk Factors for Arm Lymphedema in a Cohort of Breast Cancer Patients Followed up for 10 YearsThe clinical relevance of axillary reverse mapping (ARM): study protocol for a randomized controlled trial.Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients.Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature.Treatment of various secondary lymphedemas by microsurgical lymph vessel transplantation.Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel : Part 1: Definitions, Assessments, Education, and Future Directions.Two decades of axillary management in breast cancer.Comprehensive visualization of paresthesia in breast cancer survivors.Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer.Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study.Lymphedema of the arm and breast in irradiated breast cancer patients: risks in an era of dramatically changing axillary surgery.Using the 12-item General Health Questionnaire to screen psychological distress from survivorship to end-of-life care: dimensionality and item quality.Implementation of sentinel lymph node biopsy with blue dye outside a specialized center: can we improve quality assurance?Randomized clinical trial on the preservation of the medial pectoral nerve following mastectomy due to breast cancer: impact on upper limb rehabilitation.Morbidity and Outcomes Following Axillary Lymphadenectomy for Melanoma: Weighing the Risk of Surgery in the Era of MSLT-II.Factors associated with return to work after breast cancer treatment.
P2860
Q24804538-8720C4A0-84DC-431F-B02A-608E2F183B96Q30249050-1887E1A0-8525-4152-ACB1-330C0522B4B1Q30583480-538EC4A5-7868-4190-B355-D64A96A30027Q33237948-213A8C7F-7480-487E-832E-B7B415549F9BQ33590486-DF673A58-3262-4268-BFCF-0963A846ABA3Q33913140-289AA0BB-33BC-45A8-856C-BD6F1CB84E2DQ34134182-E5307FC2-2A1E-4508-B5C0-468094FBEEAFQ34149752-BD5A21F0-B18F-4D23-8869-A92B6A9B9E72Q34390853-1F058257-8889-497C-B8E3-93601CC36067Q34654081-2797B58F-7DC4-44D7-8995-4EAEFA9E31ECQ34704773-AC87D32F-3A8B-4AEF-8BDB-A35B0C25B8E7Q34810831-DC6B89E0-56A4-4C75-9A9C-E19D95809D8EQ35091181-AF8867B6-91D5-463A-BB17-4538C6718103Q35208321-0F2AE9A0-8346-4F2B-9083-225850395DC5Q35679960-1DDF9AF4-7AFE-4E83-8F4D-6D700263F6DAQ36648233-0A41048B-2EA8-49DE-8AE0-99D821439EEDQ36668256-A6DF798E-E04B-48E0-ACB3-16E9D7F144CCQ36741845-BE42CA90-47A4-4591-A355-C90FCEB6EE61Q36744952-CFFA6712-50D4-408D-A57E-B8462C1B40C7Q36874017-43C18EEC-392F-462F-88B2-7D672066A713Q37702991-AAF76843-AF9A-440B-B772-7FE067BE9440Q37907386-D0807E24-FA7C-4B47-8575-3565BA87548CQ37960430-02EBF58A-35E0-485D-955E-05BBE9EE1016Q38648224-131D1558-B1E8-471C-B3B7-84314E6A569FQ38928989-53A54221-5F71-428B-A8B5-6ABCBABD758AQ39256294-63B4C55B-50AC-462D-A37A-2E253867FCF1Q43611760-4FE18B6C-0BD8-4197-9513-9600F539C756Q44220848-342F1599-B263-45EF-8B7F-32FF899A941DQ44904471-6F5F05ED-5ECC-490E-BCD8-7870941A9F96Q45049218-A83D9454-ECE6-4BEE-AB11-EC63D81BC8C8Q45282276-EC6FB5DB-E568-4F87-AC1E-F01653FFDEEFQ46888846-E22A0BFD-3729-4F88-BF00-5D6E90A4006EQ47437708-0FA59930-52D5-47AA-9297-CC0D731CA63BQ48405268-6360289B-FED4-473C-B407-62E99013A90C
P2860
Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Risk, severity and predictors ...... dissection for breast cancer.
@en
Risk, severity and predictors ...... dissection for breast cancer.
@nl
type
label
Risk, severity and predictors ...... dissection for breast cancer.
@en
Risk, severity and predictors ...... dissection for breast cancer.
@nl
prefLabel
Risk, severity and predictors ...... dissection for breast cancer.
@en
Risk, severity and predictors ...... dissection for breast cancer.
@nl
P2093
P1476
Risk, severity and predictors ...... dissection for breast cancer.
@en
P2093
Coebergh JW
Crommelin MA
Repelaer van Driel OJ
Ververs JM
Vingerhoets AJ
Vreugdenhil G
Wissing JC
P304
P356
10.1016/S0959-8049(01)00067-3
P577
2001-05-01T00:00:00Z